Buzz: Will Brent Saunders split up Allergan if he loses the Restasis patent fight?
With its stock trading south of $200 after the big Restasis setback on the patent front, you can hear the growing buzz of analysts eagerly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
